Brain Function Differences in Drug-Naïve First-Episode Schizophrenia Patients With Auditory Verbal Hallucinations: Insight Matters
Auditory verbal hallucinations (AVHs)—hearing voices or sounds when no one is present—are a defining symptom of schizophrenia, affecting roughly 70% of patients. These experiences can be deeply distressing, disrupting daily life and increasing the risk of self-harm. But not all patients respond the same way: some have insight—they recognize their voices are part of their illness—while others do not. New research suggests this difference in insight is linked to distinct patterns of brain activity, especially in patients who haven’t yet taken antipsychotic medications.
Why Insight and AVHs Matter for Schizophrenia
Insight is a critical factor in schizophrenia treatment. Patients with good insight are more likely to take medication, engage in therapy, and report better outcomes. Those without insight often resist treatment, and their AVHs can worsen over time. But how does insight affect the brain—especially in “drug-naïve” patients, where medication hasn’t yet altered brain activity?
Most studies on AVHs and brain function include patients on antipsychotics, which can change how brain regions communicate. To fill this gap, researchers from Jining Medical University, Nanjing Brain Hospital, and Tianjin Mental Health Centre studied drug-naïve first-episode schizophrenia patients—people experiencing their first psychotic episode, with AVHs, who had never taken antipsychotics. They split patients into two groups: those with insight (who recognized their symptoms as part of an illness) and those without.
How the Study Was Done
The team recruited:
- 13 patients with AVHs and good insight (using the Insight and Treatment Attitudes Questionnaire, ITAQ)
- 15 patients with AVHs and poor insight
- 20 healthy controls (matched for age, sex, and education)
To measure AVH severity, they used the Auditory Hallucinations Rating Scale (AHRS), which scores factors like voice frequency, loudness, and distress. For brain imaging, they used resting-state fMRI—a scan that captures brain activity while the patient is at rest—to calculate global functional connectivity density (gFCD). This measure reflects how many connections each brain region has with others: higher gFCD means a region communicates more with the rest of the brain; lower gFCD means less communication.
Key Findings
The results, published in the Chinese Medical Journal in 2019, revealed stark differences between patients with and without insight:
1. Patients With Insight Had Fewer Brain Changes
Compared to healthy controls, patients with good insight showed decreased gFCD (less communication) only in the supramarginal gyrus—a region in the parietal lobe linked to the primary auditory cortex, which processes sound.
2. Patients Without Insight Had Widespread Brain Differences
Patients with poor insight had more extensive changes:
- Increased gFCD (more communication) in the inferior frontal gyrus (linked to language processing) and superior temporal gyrus (involved in auditory perception and voice recognition)
- Decreased gFCD (less communication) in the supplementary motor area (helps coordinate movement and speech)
When comparing the two patient groups directly, those without insight also had:
- Increased gFCD in the supramarginal gyrus and posterior superior temporal lobe
- Decreased gFCD in the frontal lobe—a brain region critical for judgment, self-awareness, and insight.
3. No Link Between AVH Severity and Brain Activity
Surprisingly, the severity of AVHs (measured by AHRS scores) did not correlate with gFCD changes in either patient group. This suggests brain differences related to insight are separate from how “bad” a patient’s voices are.
What Do These Findings Mean?
The frontal lobe is often called the brain’s “control center”—it manages decision-making, self-reflection, and the ability to recognize when something is wrong. Decreased gFCD in the frontal lobe of patients without insight likely explains why they can’t connect their symptoms to an illness: their brain’s “insight hub” isn’t functioning as well.
The increased activity in the inferior frontal and superior temporal gyri (regions tied to AVHs) adds weight to the disinhibition hypothesis of hallucinations. This theory suggests that frontal lobe impairment “unlocks” abnormal activity in other brain regions—like those processing language and sound—allowing hallucinations to occur. Because patients without insight have weaker frontal lobe connections, they can’t “turn off” this abnormal activity, leading to more severe brain changes.
For drug-naïve patients, these findings are particularly meaningful: they show that insight-related brain differences exist before medication, which means they’re part of the illness itself—not a side effect of treatment.
Limitations and Next Steps
The study has important limitations:
- Small sample size: Only 13 patients with insight and 15 without. Larger studies are needed to confirm results.
- Cross-sectional design: The study captures a “snapshot” of brain activity—we don’t know how these changes evolve over time or with treatment.
- Focus on AVHs: The study doesn’t address other schizophrenia symptoms, like delusions or negative symptoms (e.g., social withdrawal).
Future research should follow patients long-term to see how brain activity and insight change with treatment. Larger samples could also help clarify whether these brain differences are unique to schizophrenia or shared with other conditions.
Conclusion
This study offers new clues about how insight shapes brain function in schizophrenia—especially in drug-naïve patients. Patients without insight have wider, more severe brain changes, including frontal lobe impairment that may drive both their lack of insight and their AVHs. For clinicians, this means insight isn’t just a “mindset”—it’s tied to tangible brain differences. Personalized treatments that target frontal lobe connectivity (like cognitive therapy or non-invasive brain stimulation) could help improve insight and reduce AVHs in patients who need it most.
The original study was conducted by Min Chen, Chuan-Jun Zhuo, Feng Ji, Gong-Ying Li, and Xiao-Yan Ke from Jining Medical University, Nanjing Brain Hospital, and Tianjin Mental Health Centre. It was published in the Chinese Medical Journal (2019;132(18):2199–2205).
doi:10.1097/CM9.0000000000000419
Was this helpful?
0 / 0